How to buy Maravai LifeSciences Holdings stock (Maravai LifeSciences Holdings)

Maravai LifeSciences is planning an initial public offering (IPO) to raise up to $1.35 billion. The company is most well known for its mRNA and RNA products, which are used in vaccine development. Most notably, its CleanCap approach is being used in several vaccine trials for COVID-19, though it's too soon to tell if any of those particular vaccines will make it to market.

Here's what we know so far about the IPO, including how to buy in when the stock goes public.

Our top picks for where to buy Maravai Lifesciences Holdings Inc stock

Buy Maravai LifeSciences Holdings stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Maravai LifeSciences Holdings stock price (NASDAQ: MRVI)

Use our graph to track the performance of MRVI stocks over time.

Maravai LifeSciences Holdings shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$5.37
52-week range	$4.28 - $11.56
50-day moving average more info button	$6.47
200-day moving average more info button	$8.01
Wall St. target price	$9.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.67

Is it a good time to buy Maravai LifeSciences Holdings stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Maravai LifeSciences Holdings price performance over time

Historical closes compared with the close of $5.37 from 2024-12-20

1 week (2024-12-13)	-5.29%
1 month (2024-11-22)	2.87%
3 months (2024-09-20)	-36.37%
6 months (2024-06-21)	-25.83%

1 year (2023-12-22)	-18.76%
2 years (2022-12-22)	-62.47%
3 years (2021-12-22)	41.2
5 years (2019-12-18)	N/A

Is Maravai LifeSciences Holdings stock undervalued or overvalued?

Valuing Maravai LifeSciences Holdings stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Maravai LifeSciences Holdings's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Maravai LifeSciences Holdings's EBITDA

Maravai LifeSciences Holdings's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1 million.

The EBITDA is a measure of a Maravai LifeSciences Holdings's overall financial performance and is widely used to measure a its profitability.

To put Maravai LifeSciences Holdings's EBITDA into context you can compare it against that of similar companies.

• Hercules Capital (HTGC.US): USD$414.9 million
• Moderna (MRNA.US): USD$-2361999872
• Johnson-and-Johnson (JNJ.US): USD$30.1 billion

Maravai LifeSciences Holdings financials

Revenue TTM	$276.9 million
Gross profit TTM	$714 million
Return on assets TTM	-1.61%
Return on equity TTM	-42.93%
Profit margin	-81.13%
Book value	$2.44
Market Capitalization more info button	$1.4 billion

TTM: trailing 12 months

Maravai LifeSciences Holdings share dividends

We're not expecting Maravai LifeSciences Holdings to pay a dividend over the next 12 months.

You may also wish to consider:

• Hercules Capital (HTGC.US) (10.21% forward annual dividend yield)
• Johnson-and-Johnson (JNJ.US) (3.43% forward annual dividend yield)

Maravai LifeSciences Holdings share price volatility

Over the last 12 months, Maravai LifeSciences Holdings's shares have ranged in value from as little as $4.275 up to $11.555. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Maravai LifeSciences Holdings's is 0.024. This would suggest that Maravai LifeSciences Holdings's shares are less volatile than average (for this exchange).

To put Maravai LifeSciences Holdings's beta into context you can compare it against those of similar companies.

• Hercules Capital (HTGC.US): 1.341
• Moderna (MRNA.US): 1.69
• Johnson-and-Johnson (JNJ.US): 0.518

Maravai LifeSciences Holdings overview

Maravai LifeSciences Holdings, Inc. , a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services.

Frequently asked questions

What percentage of Maravai LifeSciences Holdings is owned by insiders or institutions?
Currently 1.355% of Maravai LifeSciences Holdings shares are held by insiders and 102.69% by institutions. How many people work for Maravai LifeSciences Holdings?
Latest data suggests 580 work at Maravai LifeSciences Holdings. When does the fiscal year end for Maravai LifeSciences Holdings?
Maravai LifeSciences Holdings's fiscal year ends in December. Where is Maravai LifeSciences Holdings based?
Maravai LifeSciences Holdings's address is: 10770 Wateridge Circle, San Diego, CA, United States, 92121 What is Maravai LifeSciences Holdings's ISIN number?
Maravai LifeSciences Holdings's international securities identification number is: US56600D1072